A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C] CT1812 in Healthy Adult Male Subjects
Latest Information Update: 25 Jul 2023
At a glance
- Drugs Zervimesine (Primary)
- Indications Alzheimer's disease; Cognition disorders; Dementia; Dry age-related macular degeneration
- Focus Pharmacokinetics
- Acronyms COG0108
- Sponsors Cognition Therapeutics
Most Recent Events
- 10 Feb 2022 New trial record